Trials / Recruiting
RecruitingNCT06659653
Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
Safety and Effectiveness of PRG2302 (CD19/CD22-targeting CAR-T Cells) for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Tan Jie · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Study on the Safety and Effectiveness of CD19/CD22 Chimeric Antigen Receptor T Cells in the Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRG2302 | Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose |
Timeline
- Start date
- 2024-05-24
- Primary completion
- 2027-03-31
- Completion
- 2028-03-31
- First posted
- 2024-10-26
- Last updated
- 2024-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06659653. Inclusion in this directory is not an endorsement.